Qualia Therapeutics provides an AI‑driven neurorehabilitation platform that continuously analyzes EEG data to extract six clinically validated biomarkers in under 500 ms, giving therapists real‑time feedback on patient engagement and cognitive state.
Funding
Funding not disclosed
Founders
Product
Problem
Neurorehabilitation for stroke patients often relies on generic therapy protocols and lacks real-time insight into a patient’s brain activity, making it difficult for clinicians to adjust treatment during sessions and to predict individual recovery outcomes.
Solution
Qualia Therapeutics offers an AI-driven platform that continuously analyzes EEG data to extract six validated neural biomarkers within 500 ms, providing therapists with moment‑by‑moment feedback on patient engagement and cognitive state. Its quantum‑classical machine learning models predict each patient’s likely response to therapy before the first session, enabling personalized protocol selection. The system integrates robust artifact detection and meets medical‑device safety standards, allowing closed‑loop adjustments during rehabilitation. By delivering predictive insights and real‑time guidance, the platform aims to accelerate recovery speed and improve functional outcomes for stroke survivors in clinical settings.
Target Audience
Primary customers are stroke rehabilitation centers, hospitals, and neurorehabilitation clinics seeking data‑driven, personalized therapy for their patients.
Features
- Sub‑500 ms extraction of six clinically validated EEG biomarkers for true closed‑loop therapy
- Quantum‑classical machine learning engine that forecasts individual treatment response prior to therapy initiation
- Real‑time visual feedback dashboard delivering therapist guidance on patient engagement and cognitive state
- Integrated artifact detection and safety features compliant with medical‑device regulations
- Digital twin technology that simulates patient‑specific neural responses to optimize protocol selection